Fundraising FoxBeta Cat Pharmaceuticals
Houston, US · Founded 2014 · Delaware corporation
Find your way into Beta Cat Pharmaceuticals
Each arrow is one introduction. Sign up to fill in the first one.
30 people can intro you to Jonathan
Ask David Arthur to introduce you to Jonathan P. Northrup
You →David · together at Salarius Pharmaceuticals →Jonathan
Sign up to find every way you can get introduced to Beta Cat Pharmaceuticals
- Your email: who you already know at Beta Cat Pharmaceuticals, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Beta Cat Pharmaceuticals team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
JP
Jonathan P. NorthrupCEO, Board Member, CoFounder2011–2018Jonathan P. Northrup is President, Secretary and CEO of Beta Cat Pharmaceuticals, where he has served as co-founder and board member since 2018. He spent 28 years at Eli Lilly in roles ranging from product planning to SVP of Strategy and Marketing, and subsequently founded or co-founded multiple biotechnology companies including Salarius Pharmaceuticals (NASDAQ: SLRX), Iterion Therapeutics, Stingray Therapeutics, and others focused on cancer, immune tolerance, and drug discovery platforms.
AC
Alain CappelutiChief Financial Officer
CC
Casey CunninghamCo-Chief Medical Officer
Board
KC
Kenneth CarterBoard director
JC
Joseph CunninghamBoard director
Reported raises · per SEC filings
Form D private placements$5.5M disclosed across 4 rounds · 2014–2018
▶$2.6MraisedJun 2018 · 3 investors · PharmaceuticalsRule 506(b)
▶$2.6MraisedJun 2018 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan NorthrupDirector
- James EadieDirector
- Rahul ArasExecutive Officer
- Kenneth CarterDirector
- Joe CunninghamDirector
- Uma BhattExecutive Officer
- Offering amount
- $6M
- Amount sold
- $2.6M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1.4MraisedDec 2017 · 17 investors · PharmaceuticalsRule 506(b)
▶$1.4MraisedDec 2017 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth CarterDirector
- Jonathan NorthrupExecutive Officer, Director
- Scott JordanExecutive Officer, Director
- Joseph CunninghamDirector
- Sunil SharmaExecutive Officer, Director
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- Minimum investment
- $25K
- Proceeds to insiders
- $125K
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1MraisedJul 2015 · 2 investors · BiotechnologyRule 506(b)
▶$1MraisedJul 2015 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sunil SharmaExecutive Officer, Director
- Kenneth CarterDirector
- Joseph CunninghamDirector
- Jonathan P. NorthrupExecutive Officer, Director
- Alain CappelutiExecutive Officer
- Stephen HorriganExecutive Officer
- Casey CunninghamExecutive Officer
- Offering amount
- $3M
- Amount sold
- $1M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$500KraisedJul 2014 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedJul 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alain CappelutiExecutive Officer
- Sunil SharmaExecutive Officer, Director
- Jonathan P NorthrupExecutive Officer, Director
- Kenneth C CarterDirector
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $500K
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- How much funding has Beta Cat Pharmaceuticals raised?
- Beta Cat Pharmaceuticals has disclosed $5.5M raised across 4 rounds.
- Where is Beta Cat Pharmaceuticals headquartered?
- Beta Cat Pharmaceuticals is headquartered in Houston, US.